[68Ga]Ga-NOTA-(TMVP1)2对卵巢癌患者VEGFR-3成像的首次评价

IF 2 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

American journal of nuclear medicine and molecular imaging Pub Date : 2025-04-15 eCollection Date: 2025-01-01 DOI:10.62347/FYYB3942

Xi Chen, Fei Li, Yao Si, Liping Han, Xiaoding Lou, Ling Xi, Jun Dai

{"title":"[68Ga]Ga-NOTA-(TMVP1)2对卵巢癌患者VEGFR-3成像的首次评价","authors":"Xi Chen, Fei Li, Yao Si, Liping Han, Xiaoding Lou, Ling Xi, Jun Dai","doi":"10.62347/FYYB3942","DOIUrl":null,"url":null,"abstract":"To evaluate the safety and VEGFR-3 imaging effects of [68Ga]Ga-NOTA-(TMVP1)2 in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [68Ga]Ga-NOTA-(TMVP1)2. The safety of [68Ga]Ga-NOTA-(TMVP1)2 was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 18F-FDG-positive lesions, 63.3% of which were positive for [68Ga]Ga-NOTA-(TMVP1)2. The higher expression of VEGFR-3 in [68Ga]Ga-NOTA-(TMVP1)2-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [68Ga]Ga-NOTA-(TMVP1)2 is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [68Ga]Ga-NOTA-(TMVP1)2 enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"15 2","pages":"65-73"},"PeriodicalIF":2.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089094/pdf/","citationCount":"0","resultStr":"{\"title\":\"First evaluation of [68Ga]Ga-NOTA-(TMVP1)2 for imaging VEGFR-3 in ovarian cancer patients.\",\"authors\":\"Xi Chen, Fei Li, Yao Si, Liping Han, Xiaoding Lou, Ling Xi, Jun Dai\",\"doi\":\"10.62347/FYYB3942\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To evaluate the safety and VEGFR-3 imaging effects of [68Ga]Ga-NOTA-(TMVP1)2 in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [68Ga]Ga-NOTA-(TMVP1)2. The safety of [68Ga]Ga-NOTA-(TMVP1)2 was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 18F-FDG-positive lesions, 63.3% of which were positive for [68Ga]Ga-NOTA-(TMVP1)2. The higher expression of VEGFR-3 in [68Ga]Ga-NOTA-(TMVP1)2-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [68Ga]Ga-NOTA-(TMVP1)2 is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [68Ga]Ga-NOTA-(TMVP1)2 enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.\",\"PeriodicalId\":7572,\"journal\":{\"name\":\"American journal of nuclear medicine and molecular imaging\",\"volume\":\"15 2\",\"pages\":\"65-73\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089094/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of nuclear medicine and molecular imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62347/FYYB3942\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of nuclear medicine and molecular imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62347/FYYB3942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

摘要

评价[68Ga]Ga-NOTA-(TMVP1)2在卵巢癌患者中的安全性及VEGFR-3显像效果。招募13例卵巢癌患者，采用[68Ga]Ga-NOTA-(TMVP1)2进行放射性核素显像。评估[68Ga]Ga-NOTA-(TMVP1)2在体内的安全性（包括生命体征、生化指标、心电图、过敏反应等），并探讨其对VEGFR-3的显像作用。本研究共纳入1例原发性卵巢癌患者和12例复发性卵巢癌患者，年龄在41-54岁之间。13例卵巢癌患者共49个18f - fdg阳性病灶，其中[68Ga]Ga-NOTA-(TMVP1)2阳性占63.3%。免疫组化染色发现VEGFR-3在[68Ga]Ga-NOTA-(TMVP1)2阳性卵巢癌病变中表达较高，两者呈正相关。同时，[68Ga]Ga-NOTA-(TMVP1)2是一种安全的放射性示踪剂，在人体中未发现明显的副作用。综上所述，[68Ga]Ga-NOTA-(TMVP1)2能够对卵巢癌患者中VEGFR-3进行精确的分子成像，且具有良好的安全性，为卵巢癌中VEGFR-3的体内评估提供了新的工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

First evaluation of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ for imaging VEGFR-3 in ovarian cancer patients.

To evaluate the safety and VEGFR-3 imaging effects of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ in ovarian cancer patients. 13 patients with ovarian cancer were recruited and underwent radionuclide imaging with [⁶⁸Ga]Ga-NOTA-(TMVP1)₂. The safety of [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ was assessed in vivo (including vital signs, biochemical indices, ECG, allergic reactions, etc.) and its imaging effect on VEGFR-3 was explored. A total of 1 patient with primary ovarian cancer and 12 patients with recurrent ovarian cancer, with an age range of 41-54 years, were included in the study. 13 ovarian cancer patients had a total of 49 ¹⁸F-FDG-positive lesions, 63.3% of which were positive for [⁶⁸Ga]Ga-NOTA-(TMVP1)₂. The higher expression of VEGFR-3 in [⁶⁸Ga]Ga-NOTA-(TMVP1)₂-positive ovarian cancer lesions was found by immunohistochemical staining, which was positively correlated. Meanwhile, [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ is a safe radiotracer as no significant side effects have been found in the human. In conclusion, [⁶⁸Ga]Ga-NOTA-(TMVP1)₂ enables precise molecular imaging of VEGFR-3 in ovarian cancer patients with a favourable safety profile, providing a new tool for the in vivo assessment of VEGFR-3 in ovarian cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American journal of nuclear medicine and molecular imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

自引率

4.00%

发文量

期刊介绍： The scope of AJNMMI encompasses all areas of molecular imaging, including but not limited to: positron emission tomography (PET), single-photon emission computed tomography (SPECT), molecular magnetic resonance imaging, magnetic resonance spectroscopy, optical bioluminescence, optical fluorescence, targeted ultrasound, photoacoustic imaging, etc. AJNMMI welcomes original and review articles on both clinical investigation and preclinical research. Occasionally, special topic issues, short communications, editorials, and invited perspectives will also be published. Manuscripts, including figures and tables, must be original and not under consideration by another journal.